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Good Publication Practice: Maintaining the Integrity of
Scientific Communications
Good Publication Practice (GPP) is a set of guidelines
within the health care communication industry that
encourages the responsible and ethical publication
of scientific data. GPP has its origins in the mid1990s when it first came to public awareness that
involvement of unacknowledged, industry-funded
medical writers could compromise the integrity of
scientific articles. While medical writers were initially
regarded skeptically by medical journal editors, their
valuable contribution to the accuracy and currency of
scientific communications is now fully acknowledged
and a more balanced view of the relationship between
author, sponsor and medical writer is gradually
emerging. In fact, a 2007 article in the British Medical
Journal commented that: “medical writers are not
a fifth column but are working in a fast-moving
modern environment to help disseminate scientific
information…. and their work needs to be embraced
and acknowledged…”.1 Furthermore, the World
Association of Medical Editors (WAME) urges editors
to make it clear in their instructions to authors that
medical writers can be legitimate contributors.2
However, a recent editorial in the Financial Times
makes it clear that,“Using professional writers to
improve the standard of manuscripts submitted to
medical journals is acceptable, and even desirable.
Ghost-writing, which conceals the underlying influence
and authorship, is wrong.”3 Since it is in the interest of
all parties involved in disseminating scientific data to
eliminate such questionable practices, various national
and international guidelines have been developed to
ensure that manuscripts are not only of a high quality,
but that the preparation process is beyond reproach.
The Good Publication Practice for the Pharmaceutical
Companies4 (GPPPC) guidelines were first published in
2003 and updated in 2009. These guidelines are aimed
to increase transparency and to encourage the ethical

dissemination of data. Numerous guidelines produced
by associations representing medical writers, medical
editors and the pharmaceutical industry have followed
and continue to evolve.
Authorship is key to the integrity of any written
communication, and the definition of an author given
by the International Committee of Medical Journal
Editors5(ICMJE) is widely accepted. According to
this definition, an author must make a substantial
contribution to the conception and design, acquisition
of data or analysis and interpretation of data, as well
as writing the first draft of the article (or revising
it critically) and giving final approval. The ICMJE
also stipulates that all authors must take public
responsibility for their work. If authors do use the
services of medical writers, they must always agree
with the content and outline with the writer before the
first draft is written and the two parties must maintain
contact throughout development of the manuscript.4
Given the ICMJE criteria, it is clear that medical writers
will not usually qualify to be authors, perhaps with
the exception of review articles in which the writer
performed the literature search, identified articles
and evaluated the data. However, there is universal
agreement that a medical writer’s contribution should
be clearly acknowledged in the article and any funding
disclosed.2, 4, 6 WAME goes further and considers
all parties involved in concealing medical writer
involvement to be responsible (including marketing,
communications and medical education companies)
and suggests the ‘naming and shaming’ of culprits.7
Of course, the scope of GPP guidelines goes beyond
the single issue of medical writers and covers other
areas crucial to the unbiased communication of
biomedical literature. The ICMJE and the GPPPC
discourage duplicate publications of data. Exceptions

include symposium proceedings, alternative analyses,
data grouping with other studies and publication for
different audiences.4,5 Furthermore, WAME requires
that authors disclose details of related papers they
have authored, even if they are in a different language,
in press or submitted to another journal.3 The ICMJE
and the GPPPC consortium are also among the
organizations seeking to persuade pharmaceutical
companies to publish all trial results, negative as well
as positive.4,5 To this end, the ICMJE, the GPPPC and
WAME strongly support the registration of clinical
methodology,4,5,7 while the 2007 FDA Amendment Act
goes a step further and requires that researchers also
register all trial results. This policy should go a long way
to identifying unpublished–and therefore probably
negative–data which will help to avoid a potentially
misleading weighting of results.
Conflict of interest disclosure is another area taken
very seriously by medical journal editors; the Journal
of the American Medical Association investigates all
allegations of undisclosed conflicts, emphasizing that
reporting the best available biomedical science is of
prime importance and should not be jeopardized by
such misrepresentation.8
GPP guidelines are continuing to develop and are
gaining wide acceptance by all parties involved in the
communication and dissemination of biomedical
information. The principles of clear, unbiased and
ethical reporting of results, opinions and ideas can only
be of benefit to the medical community in particular
and society as a whole. 
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